AstraZeneca Signs an Exclusive Promotion Agreement with Luye Pharma for its Xuezhikang in China

 AstraZeneca Signs an Exclusive Promotion Agreement with Luye Pharma for its Xuezhikang in China

AstraZeneca Signs an Exclusive Promotion Agreement with Luye Pharma for its Xuezhikang in China

Shots:
  • AstraZeneca to get exclusive promotion rights in China including Taiwan, Hong Kong, Singapore, Malaysia for Luye’s Xuezhikang capsules. Luye Pharma will retain its IPR, commercialization rights, asset rights & registration permit rights
  • The focus of the agreement is to promote Xuezhikang in cardiovascular disorders and strengthening Luye’s footprints in cardiology, with its further expansion in the US and EU
  • Xuezhikang is a lipid-regulating candidate used for maintaining abnormal blood lipids and is evaluated in P-II trial for patients with LDL-C

Click here to read full press release/ article | Ref:  Luye Pharma | Image: LinkedIn

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post